Search for Terms or Answers
Bimekizumab BEATS Risankizumab in PsA 24 week results by ACR50 from H2H BE-BOLD: - wk 4 19.9% vs. 7.2% - wk 16 49.1% vs. 38% - wk 24 54.9% vs. 43.8% More fungal infx in IL17 group as expected, mild-mod Practice-changing results for PsA @RheumNow #ACRbest #ACR26 Abst2804 https://t.co/3GxVLNs1td
Ab#2804 #ACR26 @RheumNow BE BOLD: Bimekiz v Risankiz in PsA, 24w H2H P3B W16 (primary endpt): ACR50: BKZ 49% v 38% RZB, p=.006, W24: 56% v 44% MDA, ACR50+PASI100 NOT signif PASI100: BKZ earlier, equal later BKZ - better for jts, earlier skin but equal later, more Candida #ACRBest https://t.co/q6g6zQMutY
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.